✨ MIT engineers have developed a new mRNA adjuvant that supercharges T-cell responses, showing promise for more powerful cancer vaccines and stronger protection against infectious diseases.

🔬 In mouse studies, this new adjuvant, delivered via lipid nanoparticles to the spleen, led to the complete eradication of most tumors, even without specific cancer antigens, and significantly boosted T-cell responses to influenza and Covid-19 vaccines by 10-15 fold.

🧬 This advance uses mRNA to encode genes (IRF8 and NIK) that reprogram immune cells internally, creating a more potent and durable anti-tumor response and potentially improving the effectiveness of existing cancer immunotherapies like checkpoint inhibitors.

#CancerVaccine #Immunotherapy #VaccineTechnology

💡 A pilot trial tested the anti-inflammatory drug tocilizumab on 30 participants with moderate-to-severe depression who hadn't responded to standard treatments. Early findings suggest it may reduce depression symptoms, fatigue, anxiety, and improve quality of life compared to a placebo.

🔬 The study focused on inflammation-related depression, as about one-third of individuals with depression show signs of inflammation. Tocilizumab targets IL-6, a key inflammatory protein linked to depression.

📈 Participants receiving tocilizumab showed greater improvements in depression severity, fatigue, anxiety, and quality of life. Additionally, 54% achieved depression remission compared to 31% in the placebo group, with a Number Needed to Treat (NNT) of 5.

#DepressionResearch #Immunotherapy #MentalHealth

💉 A new study shows combining the vaccine intismeran with immunotherapy (pembrolizumab/Keytruda) reduced the risk of skin cancer recurrence by 49% five years after surgery.

📉 This combination therapy also lowered the risk of distant cancer spread by 59% and improved overall survival to 92.2% compared to immunotherapy alone (71.3%).

🔬 The findings from the phase 2b KEYNOTE-942 trial, involving 107 patients, are being presented at the 2026 American Society of Clinical Oncology meeting on June 1 and published in the Journal of Clinical Oncology.

#CancerResearch #Melanoma #Immunotherapy

🔬 UCalgary study discovers a way to make colorectal cancer visible to immunotherapy by eliminating a single gene.

💉 In mouse models, this gene edit led to 100% tumor eradication when combined with immunotherapy.

💡 The research identifies a protein secreted by resistant tumors that hides them from the immune system, a mechanism that might also apply to other solid tumors like pancreatic and lung cancer.

#CancerResearch #Immunotherapy #ColorectalCancer

Experimental treatment directly kills prostate tumor cells while reawakening antitumor immunity: « Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing anti-tumor immunity. »

Read Full Article

#ProstateCancer #Immunotherapy #NanoparticleTherapy

🔬 New Cellular Model for Rare Cancer Developed: Researchers at the University of Turku, Finland, have created a powerful lab model using gene editing to study BAP1-deficient melanomas, a type of rare tumor resistant to current immunotherapies.

🧬 Bridging the Research Gap: This new model, created with CRISPR-Cas9, accurately mimics human BAP1-deficient melanoma in animals with functioning immune systems, a crucial step to understand how these tumors evade immune attacks.

💡 Accelerating Treatment Development: The lack of a suitable model has slowed drug development. This breakthrough offers a platform to study BAP1 loss and test new immunotherapy combinations for hard-to-treat cancers, going beyond melanoma.

#CancerResearch #Immunotherapy #MedicalBreakthrough

Vaccine Against Brain Tumors Shows Promising Long-Term Results: 33 patients with high-grade astrocytomas, the most common form of glioma, received vaccine that trains the immune system to recognize and fight tumor cells. 66% were still alive after 8 years, and in 42%, the disease had not progressed.

Read Full Article

#BrainTumorTreatment #Immunotherapy #GlioblastomaResearch

🧠 New Brain Cancer Vaccine Shows Promise in Clinical Trial
A peptide vaccine targeting a common genetic mutation in gliomas has shown remarkable results in a Phase 1 trial (NOA 16) involving 33 patients with high-grade astrocytomas.

📈 Significantly Improved Long-Term Survival
After up to eight years of follow-up, 66% of participants were still alive, with 42% showing no disease progression. This significantly exceeds previous median survival times of 2.5-5 years for aggressive tumor types.

🔬 Immune Response Linked to Better Outcomes
Patients whose immune systems responded strongly to the vaccine, activating T and B cells, had better long-term prognoses. Activated immune cells were observed migrating into tumors in patients with controlled disease.

💡 Potential for Standardized Immunotherapy
This vaccine targets a common mutation, allowing for a standardized approach unlike individual patient vaccines. Booster shots may prolong effectiveness without additional side effects.

#BrainCancer #Immunotherapy #ClinicalTrial

Study in a mouse model, have shown for the first time that a yeast-based food supplement helps the body to make stronger immune cells that can fight cancer

Read Full Article

#Immunotherapy #CancerResearch #YeastSupplement

New cancer vaccine redirects COVID-19 infection and vaccination. By pairing tumor-specific antigens with SARS-CoV-2 Spike protein epitopes, vaccine converts antiviral memory into antitumor immunity. In humanized mouse models of melanoma and breast cancer, it slowed tumor growth, improved survival.

Read Full Article

#CancerVaccine #Immunotherapy #OncologyResearch

🔬 New Cancer Vaccine Platform PROTEXI Leverages COVID-19 Immunity
Scientists have developed PROTEXI, a novel vaccine platform that uses pre-existing immune memory from COVID-19 infection and vaccination to help the body fight cancer. Published July 27, 2026, in Nature Communications, this approach aims to redirect existing antiviral immune responses to recognize and destroy tumors, potentially overcoming challenges with current cancer vaccines.

💪 PROTEXI Shows Promise in Preclinical Cancer Models
In tests on melanoma and breast cancer models, PROTEXI demonstrated the ability to slow tumor growth, improve survival, and make immune-evading tumors more recognizable to the immune system. The vaccine strengthened natural defenses and created long-lasting immune memory, showing enhanced effectiveness when combined with other immunotherapies.

🤝 Collaborative Effort Advances PROTEXI to Clinical Trials
A partnership between Celloram Inc., University Hospitals, and Case Western Reserve University has led to the advancement of PROTEXI. The platform is moving towards first-in-human clinical trials for sarcoma patients, aiming to translate these scientific discoveries into a new precision cancer immunotherapy.

#CancerResearch #Immunotherapy #COVID19

Arginine helped mice fight cancer and flu

Read Full Article

#CancerResearch #Immunotherapy #FluPrevention

Experimental treatment kills prostate tumor cells while reawakening antitumor immunity

Read Full Article

#ProstateCancer #Immunotherapy #CancerResearch

✨ Experimental nanoparticles show promise in fighting prostate tumors by directly killing cancer cells and boosting the body's immune system.

🔬 In preclinical studies using mouse models of aggressive prostate cancer, these ultrasmall silica nanoparticles, called C' dots, induced complete tumor remissions.

💊 The particles activate a natural cell-death process in tumor cells and convert the tumor's immune environment from "cold" (inactive) to "hot" (active against cancer), enhancing the effectiveness of other immunotherapies.

🚀 Combination treatments involving C' dots with existing immunotherapies led to complete or near-complete remissions and indefinite survival in a significant portion of treated mice.

#ProstateCancer #CancerResearch #Immunotherapy

LSD helps the immune system fight bowel cancer

Read Full Article

#LSD #Immunotherapy #CancerResearch

mRNA immunotherapy eliminates pancreatic tumors in mice: Approximately 50% of mice with pancreatic cancer treated with the mRNA immunotherapeutic cocktail saw complete tumor responses and more impressively, remained disease free for a year, even after treatment had been stopped.

Read Full Article

#mRNAImmunotherapy #PancreaticCancer #CancerResearch breakthroughs should be one word per hashtag; but instruction says format with # and separate with spaces. Ensure exactly three hashtags, no extra text. Use common tags: #mRNA, #Immunotherapy, #PancreaticCancer? They want high-traffic. Use #mRNA #Immunotherapy #PancreaticCancer? But they require hashtags with #. Should be readable: #mRNAImmunotherapy #PancreaticCancer #CancerResearch. But 3. Let's pick: #mRNAImmunotherapy #PancreaticCancer #CancerResearch

Cancer cells release antioxidants to prevent immune cells from destroying them

Read Full Article

#CancerResearch #Immunotherapy #Antioxidants

🔬 Scientists discovered that cancer cells release natural antioxidants (like PRDX1) to deactivate immune cells (T cells) that are supposed to destroy them.

🔬 T cells actually need reactive oxygen species (molecules that were previously thought to be damaging) to activate and fight cancer. Tumors exploit this by releasing antioxidants to "smother" T cells.

🔬 In lab studies using mice, blocking cancer cells' ability to produce these antioxidants made them more responsive to existing cancer immunotherapies.

🔬 This new understanding could lead to ways to improve cancer immunotherapies, potentially by using "pro-oxidants" to boost T cell activity, rather than antioxidants, which might inadvertently harm the immune response.

#CancerResearch #Immunotherapy #MedicalBreakthrough

✨ Cancer Breakthrough: CAR T-Cell Therapy Shows Promise Against Solid Tumors
A 3-year-old boy with advanced liver cancer (hepatoblastoma) achieved complete remission with an experimental CAR T-cell therapy, a significant step as this treatment has historically been limited to blood cancers. The therapy genetically engineers a patient's immune cells to fight cancer.

🔬 Personalized Treatment Targets Rare Cancer
The boy, whose cancer had spread to his lungs and potentially bones, received two doses of GPC3-CAR T-cell therapy, an experimental treatment designed to recognize a protein common in liver cancers. This approach, detailed in The New England Journal of Medicine, is showing potentially life-saving results for solid tumors, even in a chemotherapy-resistant case.

🌟 Hope for Durable Remission
After receiving the CAR T-cell infusions, the boy showed a partial response and, eight weeks later, follow-up scans revealed no remaining signs of disease except for scarring. He remained disease-free 12 months later, demonstrating the potential for durable responses outside of traditional chemotherapy.

#CancerResearch #Immunotherapy #CARtCell

🔬 Scientists have engineered probiotic bacteria (E. coli Nissle 1917) to act as tiny drug factories within tumors, producing chemotherapy while stimulating the immune system.

🔬 In tests on mice with colorectal tumors, this approach led to complete regression in 3 out of 7 tumors (43%), showing promise in targeting cancer cells while potentially reducing systemic side effects.

🔬 The engineered bacteria were programmed to deliver a triple-whammy: producing chemotherapy (5-FU) directly in the tumor, acting as an immune stimulant, and blocking a tumor's immune-suppressing mechanism.

#CancerResearch #Probiotics #Immunotherapy